Testing OPB-101 for platinum-resistant ovarian cancer
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a new treatment called OPB-101 for people with a type of ovarian, peritoneal, or fallopian tube cancer that has stopped responding to platinum chemotherapy. The goal is to see if it is safe and if it can help shrink or slow the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- Your cancer (high-grade serous type) must have come back within 6 months of your last platinum-based chemo.
- You must have had at least 2 different types of chemotherapy before, including a platinum-based one.
- Your tumor must be measurable (can be seen on scans).
- You must be able to do your daily activities with little or no help (ECOG score 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug called OPB-201 for people with certain gynecologic cancers (endometrial, ovarian, peritoneal, or fallopian tube) that have come back after treatment. The drug is designed to help your immune system recognize and fight cancer cells that carry a specific marker called PRAME.
This trial tests IN10018 together with standard chemotherapy in people with high-grade serous ovarian (or related) cancer that has come back or progressed soon after platinum treatment. The goal is to see if adding IN10018 can improve cancer control and safety.
This trial tests a new cell therapy (GB-5267) for people with platinum-resistant ovarian, peritoneal, or fallopian tube cancer. It requires multiple tumor biopsies and aims to see if the treatment can help when standard chemo stops working.
This study tests a new combination treatment for people with advanced ovarian, fallopian tube, or primary peritoneal cancer that has progressed after at least two prior treatments. The aim is to see if this treatment can help shrink tumors and improve outcomes.
This trial tests a new drug called ABBV901, given alone or with other anticancer drugs, for people with advanced ovarian, fallopian tube, or primary peritoneal cancer. The goal is to see how well it works and how it affects the body.
This trial tests if adding the drug IN10018 to standard chemotherapy (liposomal doxorubicin) can help women with ovarian cancer that has stopped responding to platinum-based treatments. It aims to see if the combination works better than chemotherapy alone.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.